Global Intravenous Immunoglobulin Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Intravenous Immunoglobulin Market is presumed to reach the market size of nearly USD 27 Billion by 2032 from USD 13.3 Billion in 2023 with a CAGR of 8.19% under the study period 2024-2032.

Intravenous Immunoglobulin (IVIG) refers to a therapy that helps in treating patients with antibody deficiencies. It is a blood product made by immunoglobulin's (antibodies) from the plasma of thousands of healthy people to fight infections. Immunoglobulin's are glycoprotein's which are produced from the plasma cells. As IVIG is prepared from plasma, it is highly purified so the chances of developing a blood-borne infection are exceptionally low. This therapy helps in treating a large number of diseases such as kawasaki disease, lupus, guillain-barre syndrome, myositis, chronic inflammatory demyelinating polyneuropathy (CIDP) and also immune deficiencies such as immune thrombocytopenia. In addition to this it is also used for treating some neurological diseases such as multiple sclerosis or myasthenia gravis.

MARKET DYNAMICS

The global Intravenous Immunoglobulin Market is majorly driven by growing elderly population, high prevalence of immunodeficiency diseases, growing number of hemophilic patients, increase in acceptance of IVIG treatments and rising investment in intravenous immunoglobulin medication projects. Increasing number of patients with immunodeficiency disorders is the major factor boosting the demand of Intravenous Immunoglobulin therapy. As per National Institute of Allergy and Infectious diseases (NIAID) there are over 200 different forms of primary immune deficiency diseases (PIDDs) and around 500,000 people in the United States suffering from such PIDDS.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Intravenous Immunoglobulin. The growth and trends of Intravenous Immunoglobulin industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Intravenous Immunoglobulin market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

Hypogammaglobulinemia
CIPD
Immunodeficiency Diseases
Congenital AIDS
Chronic Lymphocytic Leukemia
Myasthenia Gravis
Multifocal Motor Neuropathy
ITP
Kawasaki Disease
Guillain-barre Syndrome
Others

By Distribution Channel

Hospital Pharmacy
Specialty Pharmacy
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Intravenous Immunoglobulin market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Intravenous Immunoglobulin market include Biotest AG, Baxter International Inc., Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc., Kedrion Biopharma, BDI Pharma Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11213403

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. INTRAVENOUS IMMUNOGLOBULIN - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Application
- 3.7.2 Market Attractiveness Analysis By Distribution Channel
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET ANALYSIS BY APPLICATION

5.1. Overview By Application
5.2. Historical and Forecast Data
5.3. Analysis By Application
5.4. Hypogammaglobulinemia Historic and Forecast Sales By Regions
5.5. CIPD Historic and Forecast Sales By Regions
5.6. Immunodeficiency Diseases Historic and Forecast Sales By Regions
5.7. Congenital AIDS Historic and Forecast Sales By Regions
5.8. Chronic Lymphocytic Leukemia Historic and Forecast Sales By Regions
5.9. Myasthenia Gravis Historic and Forecast Sales By Regions
5.10. Multifocal Motor Neuropathy Historic and Forecast Sales By Regions
5.11. ITP Historic and Forecast Sales By Regions
5.12. Kawasaki Disease Historic and Forecast Sales By Regions
5.13. Guillain-barre Syndrome Historic and Forecast Sales By Regions
5.14. Others Historic and Forecast Sales By Regions

6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL

6.1. Overview By Distribution Channel
6.2. Historical and Forecast Data
6.3. Analysis By Distribution Channel
6.4. Hospital Pharmacy Historic and Forecast Sales By Regions
6.5. Specialty Pharmacy Historic and Forecast Sales By Regions
6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE INTRAVENOUS IMMUNOGLOBULIN COMPANIES

8.1. Intravenous Immunoglobulin Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF INTRAVENOUS IMMUNOGLOBULIN INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Biotest AG
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Baxter International Inc.
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Octapharma AG
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. LFB Biotechnologies
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Grifols SA
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. CSL Behring
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. China Biologics Products Inc.
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Kedrion Biopharma
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. BDI Pharma Inc
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies